The role of PPARγ in prostate cancer development and progression

Hartley, A. and Ahmad, I. (2023) The role of PPARγ in prostate cancer development and progression. British Journal of Cancer, 128(6), pp. 940-945. (doi: 10.1038/s41416-022-02096-8) (PMID:36510001) (PMCID:PMC10006070)

Abstract

Advanced and metastatic prostate cancer is often incurable, but its dependency on certain molecular alterations may provide the basis for targeted therapies. A growing body of research has demonstrated that peroxisome proliferator-activated receptor gamma (PPARγ) is amplified as prostate cancer progresses. PPARγ has been shown to support prostate cancer growth through its roles in fatty acid synthesis, mitochondrial biogenesis, and co-operating with androgen receptor signalling. Interestingly, splice variants of PPARγ may have differing and contrasting roles. PPARγ itself is a highly druggable target, with agonists having been used for the past two decades in treating diabetes. However, side effects associated with these compounds have currently limited clinical use of these drugs in prostate cancer. Further understanding of PPARγ and novel techniques to target it, may provide therapies for advanced prostate cancer.

• Item Type: Articles
• Status: Published
• Refereed: Yes
• Glasgow Author(s) Enlighten ID: Ahmad, Dr Imran and Hartley, Mr Andrew
• Authors: Hartley, A., and Ahmad, I.
• College/School: College of Medical Veterinary and Life Sciences > School of Cancer Sciences
• Journal Name: British Journal of Cancer
• Publisher: Springer Nature
• ISSN: 0007-0920
• ISSN (Online): 1532-1827
• Published Online: 12 December 2022
• Copyright Holders: Copyright © 2022 The Authors
• First Published: First published in British Journal of Cancer 128(6): 940-945
• Publisher Policy: Reproduced under a Creative Commons License

Project Code	Award No	Project Name	Principal Investigator	Funder's Name	Funder Ref	Lead Dept
172068		Identification and Validation of New Therapeutic Targets in Enzalutamide-Resistant Prostate Cancer	Imran Ahmad	Cancer Research UK (CRUK)	C49745/A19661	Institute of Cancer Sciences